News

Press Releases

Search

Press Releases

Totus Medicines

PRESS RELEASES 05.06.2026

Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026

Totus Medicines

PRESS RELEASES 04.30.2026

Totus Medicines to Present Interim Phase 1b Clinical Data for TOS-358 + Fulvestrant Doublet Therapy in HR+/HER- Breast Cancer Patients at ESMO Breast Cancer Annual Congress 2026

Totus Medicines

PRESS RELEASES 04.16.2026

Totus Medicines to Present First-in-Class Covalent IRF5 Inhibitor Data at AAI IMMUNOLOGY2026

Totus Medicines

PRESS RELEASES 03.18.2026

Totus Medicines Presents Phase 1a Clinical Data for TOS-358, a Covalent PI3Ka Inhibitor, at ESMO TAT 2026

Totus Medicines

PRESS RELEASES 02.12.2026

Totus Medicines to Present Updated Phase 1 Clinical Data for TOS-358 at ESMO Targeted Anticancer Therapies Congress 2026

Jp morgan healthcare conference 2026 locumpedia events calendar

PRESS RELEASES 01.06.2026

Totus Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

PRESS RELEASES 01.27.2025

Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer

Zelanna Goldberg

PRESS RELEASES 01.10.2025

Totus Medicines Announces Successful Completion of a Phase 1 Dose-Escalation Study and Initiation of an Expansion Trial Evaluating TOS-358 and Appoints Zelanna Goldberg as Chief Medical Officer

PRESS RELEASES 05.16.2024

Totus Medicines Announces Strategic Multi-Target Research Collaboration with Lilly

PRESS RELEASES 12.15.2023

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Maraganore John HS3

PRESS RELEASES 10.19.2023

John Maraganore, Ph.D. Joins Totus Medicines' Scientific Advisory Board

Neil undruggable

PRESS RELEASES 09.27.2023

Totus Makes a Mark at Future of R&D Week in Boston

Clinical trial 2

PRESS RELEASES 04.13.2023

Totus Medicines Announces First Patient Dosed in Phase 1 Trial of TOS-358 for the Treatment Of Select Solid Tumors

PRESS RELEASES 04.12.2023

Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero

PRESS RELEASES 04.10.2023

Totus Medicines Announces Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

PRESS RELEASES 01.04.2023

BioSpace Names Most Promising New Biopharma Companies to Watch in 2023 PR Newswire 01 04 2023

PRESS RELEASES 10.11.2022

Totus Medicines CEO to Present at Next-Generation Undruggable Conference

PRESS RELEASES 05.05.2022

Totus Medicines Announces Global Pharma Leader Tom Hughes as Board Chair & Creation of Scientific Advisory Board

PRESS RELEASES 03.31.2022

Totus Medicines Announces New San Francisco Bay Area Headquarters & Expanded Lab Space

PRESS RELEASES 03.24.2022

Totus Medicines Partners with Mila to Advance Drug Discovery Technologies in Mission to Treat the Untreatable

Ovid Trifan CMO

PRESS RELEASES 02.23.2022

Expert Clinical Developer Dr. Ovid Trifan and Veteran Drug Hunter Dr. Wei Chen Bring Decades of Complex Drug Development Experience to Totus Medicines

JPM hc conference graphic

PRESS RELEASES 01.11.2022

Totus Medicines to Present at 2022 J.P. Morgan HealthCare Conference

Daisy Chhokar CPO

PRESS RELEASES 01.06.2022

Totus Medicines Appoints Chief People Officer Daisy Chhokar and Chief Financial Officer Sam Singer to Senior Leadership Team

PRESS RELEASES 12.09.2021

Totus Medicines Emerges from Stealth with Revolutionary Drug Program Targeting PI3K-Alpha Oncogene

PRESS RELEASES 12.09.2021

Totus Medicines Emerges from Stealth with Revolutionary Drug Program Targeting PI3K-Alpha Oncogene

Platform Totus Meds Lab

A breakthrough cancer drug already, and more on the way.